How does the combination of stiripentol and fenfluramine impact gabaergic transmission?

How does stiripentol boost GABA activity when paired with fenfluramine?

Stiripentol increases GABA levels in the brain by inhibiting its reuptake and metabolism. It also directly potentiates GABA_A receptors, prolonging their opening time and raising neuronal inhibition. When added to fenfluramine, these effects combine with fenfluramine’s serotonin release to produce stronger overall suppression of seizures.

Why do patients search for this pairing?

Patients and clinicians track this duo mainly for Dravet syndrome, where fenfluramine alone is approved and stiripentol is often added as adjunctive therapy. The pair appears in clinical guidelines as a sequential or simultaneous treatment step.

What happens if you add stiripentol to fenfluramine therapy?

Adding stiripentol raises fenfluramine blood levels because stiripentol inhibits CYP2D6 and CYP3A4, enzymes that abbot fenfluramine metabolism. Dose adjustments are usually required to keep the fenfluramine dose below 0.4 mg/kg/day when both drugs are present. Dose careful monitoring of appetite loss and sleep disturbances occurs during transition periods.

How does the pair affect GABAergic inhibition differently than each alone?

The combination strengthens GABAergic transmission through complementary routes. Stiripentol’s direct receptor potentiation and reuptake blockade combine with fenfluramine’s upstream serotonin-mediated increase in GABA release. This dual action produces a more persistent inhibition profile compared with either agent acting alone.

Can biosimilars or generics affect this mechanism?

No biosimilars exist for either compound. Generics for stiripentol are available in several countries but remain under active patent protection in the U.S. until 2030.